BioSpace News Archive

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”) today announced that previously reported data from its BackBeat Cardiac Neuromodulation Therapy™ (CNT™) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) programs will be featured in upcoming oral presentations at the Cardiovascular Research Technologies (CRT) 2023 Meeting, which is being held in Washington, DC, from February 25 – 28, 2023.

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”) announces that Kevin Chung, M.D., Chief Medical Officer, will discuss the Company’s Selective Cytopheretic Device (SCD) in a presentation at the 5th Chronic Kidney Disease Drug Development Summit (CKD5) in Boston on March 7, 2023 at 10 a.m. Eastern Time.

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 43nd Annual Healthcare Conference, which is being held March 6-8, 2023, at the Boston Marriott Copley Place in Boston, Massachusetts.

Aural Analytics, Inc., a leader in clinical-grade speech analytics, today announced that its speech analytics platform facilitated differentiation and provided critical insights into the effectiveness of Pridopidine in clinical trials.

Agilent Technologies Inc. announced their xCELLigence RTCA HT platform now integrates with the BioTek BioSpa 8 Automated Incubator.

Astria Therapeutics, Inc. (Nasdaq:ATXS) presented new STAR-0215 data in two poster presentations at the American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas that demonstrate early proof-of-concept for STAR-0215’s profile as a long-acting preventative therapy for HAE.

Neogen Corporation has continued to report successes with the advancement of its Neogen® Analytics software program.

Living in areas of the United States with higher levels of air pollution is associated with an increased risk of Parkinson’s disease, according to a preliminary study released February 23, 2023, that will be presented at the American Academy of Neurology’s 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.

Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX–102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.